Skip to content

Advertisement

  • Poster presentation
  • Open Access

Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Journal of the International AIDS Society200811 (Suppl 1) :P45

https://doi.org/10.1186/1758-2652-11-S1-P45

  • Published:

Keywords

  • Ritonavir
  • Raltegravir
  • Maraviroc
  • Etravirine
  • Generalize Linear Regression

Purpose of the study

With the availability of new drug classes, the full suppression is a realistic goal even for heavily pre-treated patients. We prospectively evaluated the magnitude of CD4 recovery (CR) in this setting.

Methods

We decided to simultaneously screen triple class failing patients (pts) followed at San Raffaele Hospital in three Expanded Access Programs: raltegravir (MK0518-023), maraviroc (A4001050), etravirine (TMC125-C214). Salvage therapy was prescribed according to: viral tropism, screening genotype and previous resistance tests. Data were collected at baseline (BL) and at 4, 12, 24, 36 and 48 weeks. Generalized linear regression model was applied. Results are reported as median (Q1–Q3).

Summary of results

Up to date, 68 pts reached week 24 (W24) without modification of the initial regimen; age 44.5 (41.7–49.9) years, 17 (25%) women, 10 (17.2%) IVDU, infected since 15.0 (12.5–18.4) years, ARV exposure of 13.0 (11.6–15.4) years, CDC C stage 32 (47%). At BL: CD4 195 (87–306) cells//μL; CD4% 11.8 (7.0–17.5), HIV-RNA 4.2 (3.8–5.0) log10 copies/mL and CD4 nadir 73 (22–178) cells/μL. No difference in BL characteristics were found according to the group regimen prescribed. (Table 1.)

Table 1

 

N

BL HIV-RNA

BL CD4

W24 CD4

Group A: RAL+MVC+ETR

15

4.2(3.9–5.1)

276(90–528)

552(398–718)

Group B: RAL + MVC or ETR + PI sparing OBT**

17

4.0(3.9–4.7)

197(94–295)

378(330–447)

Group C: RAL + MVC or ETR +PI/r* based OBT**

20

4.7(3.8–5.3)

160(63–198)

306(239–361)

Group D: RAL + PI/r* based OBT**

16

4.2(3.6–4.9)

240(121–329)

349(276–504)

*in 33/36 darunavir/r **OBT = optimized background therapy.

At week 24, 14 (93%), 13 (76%), 14 (74%), 15 (94%) had HIV-RNA <50 copies/mL in group A, B, C, D, respectively (p = 0.238).

At multivariable analysis, a significantly different CR was related to therapy group (p = 0.035) and positively related to BL HIV-RNA (p = 0.049). CR was higher in group A (adjusted mean: 214.8 ± 37.3) than group B (129.2 ± 33.5, p = 0.062) or group C (115.7 ± 30.5, p = 0.023) or group D (91.7 ± 33.3, p = 0.005). No independent effect of age (p = 0.834), gender (p = 0.392), HIV risk factor (p = 0.522), CD4% (p = 0.297) and CD4 nadir (p = 0.195) was observed. Despite the high pill number, RAL +MVC+ETR were very well tolerated; serious adverse events were diagnosed in two pts: spondylodiscitis (one), anal cancer (one).

Conclusion

Salvage therapy with RAL+ MVC+ETR showed an excellent short-term CD4 recovery. Reasons for this success could include: presence of active drugs blocking consecutive targets of viral replication, high doses of MVC required with this regimen, avoidance of ritonavir and NRTI toxicity.

Authors’ Affiliations

(1)
San Raffaele Scientific Institute, Milan, Italy

Copyright

© Nozza et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement